The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy

The prognosis for people with the high-grade brain tumor glioblastoma is very poor, due largely to low cell death in response to genotoxic therapy. The transcription factor BCL6, a protein that normally suppresses the DNA damage response during immune cell maturation, and a known driver of B-cell ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabre, Marie-Sophie, Stanton, Nicole M., Slatter, Tania L., Lee, Samuel, Senanayake, Dinindu, Gordon, Rosemary M. A., Castro, M. Leticia, Rowe, Matthew R., Taha, Ahmad, Royds, Janice A., Hung, Noelyn, Melnick, Ari M., McConnell, Melanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176076/
https://www.ncbi.nlm.nih.gov/pubmed/32320427
http://dx.doi.org/10.1371/journal.pone.0231470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176076/
https://www.ncbi.nlm.nih.gov/pubmed/32320427
http://dx.doi.org/10.1371/journal.pone.0231470

Ejemplares similares